Ablexis Announces Progress in Its Intellectual Property on AlivaMab Mouse and Immunoglobulin Locus Engineering

SAN DIEGO--(BUSINESS WIRE)-- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today provided an update on its intellectual property portfolio covering its AlivaMab Mouse platform and its groundbreaking design and engineering of synthetic human/mouse immunoglobulin transgenes. The expanded intellectual property portfolio includes claims covering the unique compositions of the AlivaMab antibody, the design features of its immunoglobulin transgenes, including synthetic variable gene segments under the control of mouse regulatory elements, and mammalian cells and rodents comprising the transgenes.

Larry Green, Ph.D., Chief Executive Officer of Ablexis and AlivaMab Discovery Services, and Dr. Hiroaki Shizuya designed the transgenes to the single nucleotide level in silico and oversaw their synthesis in vitro, yielding chimeric human and mouse coding and non-coding sequence immunoglobulin transgenes optimized for more efficient antibody drug discovery and development.

“Patent offices around the world are recognizing the inventive nature of Ablexis’ designs and engineering of AlivaMab Mouse and the antibodies it produces,” said Dr. Green. “The AlivaMab Mouse is the only transgenic animal incorporating fully synthetic, autonomously functioning immunoglobulin transgenes with a curated repertoire of variable gene segments and producing a unique part-human/part-mouse antibody composition. As a result, the AlivaMab Mouse platform increases efficiencies and reduces risks in antibody drug discovery and development.”

Issued patents include Australian patents 2009298458 and 2011234988, Canadian patent 2787498, European patent 2553100, Korean patents 10-1667440, 10-1826224, 10-1830020 and 10-1831117, New Zealand patents 586149, 592308 and 601171, and United States patents 9,346,873 and 9,580,491.

About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at info@ablexis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181113005055/en/